Cargando…

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden

Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967–20...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemminki, Kari, Försti, Asta, Hemminki, Akseli, Ljungberg, Börje, Hemminki, Otto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219161/
https://www.ncbi.nlm.nih.gov/pubmed/34157049
http://dx.doi.org/10.1371/journal.pone.0253236
_version_ 1783710876421849088
author Hemminki, Kari
Försti, Asta
Hemminki, Akseli
Ljungberg, Börje
Hemminki, Otto
author_facet Hemminki, Kari
Försti, Asta
Hemminki, Akseli
Ljungberg, Börje
Hemminki, Otto
author_sort Hemminki, Kari
collection PubMed
description Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967–2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.
format Online
Article
Text
id pubmed-8219161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82191612021-07-07 Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden Hemminki, Kari Försti, Asta Hemminki, Akseli Ljungberg, Börje Hemminki, Otto PLoS One Research Article Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967–2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1. Public Library of Science 2021-06-22 /pmc/articles/PMC8219161/ /pubmed/34157049 http://dx.doi.org/10.1371/journal.pone.0253236 Text en © 2021 Hemminki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hemminki, Kari
Försti, Asta
Hemminki, Akseli
Ljungberg, Börje
Hemminki, Otto
Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title_full Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title_fullStr Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title_full_unstemmed Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title_short Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
title_sort progress in survival in renal cell carcinoma through 50 years evaluated in finland and sweden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219161/
https://www.ncbi.nlm.nih.gov/pubmed/34157049
http://dx.doi.org/10.1371/journal.pone.0253236
work_keys_str_mv AT hemminkikari progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT forstiasta progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT hemminkiakseli progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT ljungbergborje progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT hemminkiotto progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden